All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .
Biochem/physiol Actions
RNF213 (ring finger protein 213) gene encodes a protein containing a C3HC4-type RING finger domain. This domain is capable of binding to two atoms of zinc, thereby mediating protein-protein interactions. It contains an AAA domain that has ATPase activity and is abundantly expressed in spleen and leukocytes. The AAA domain has a ring-shaped structure and mediates several biophysical and mechanical processes. It also functions as a ubiquitin ligase and may regulate vascular development. The gene is a susceptibility gene for Moyamoya disease, an idiopathic human cerebrovascular disorder characterized by progressive stenosis and abnormal collateral vessels.
